Abstract
Background: Inflammation influences cancer growth and treatment susceptibility. We investigated the influence of radiochemotherapy and radiotherapy on serum interleukine-6 (IL-6), C-reactive protein (CRP), and transforming growth factor-β (TGF-β) levels in patients with head and neck cancers. Methods: Of 26 patients enrolled, 8 received radiotherapy (SIB-IMRT, 2.25 Gy/fraction, 30 fractions) and 18 received radiochemotherapy [cisplatin 100 mg/m 2 and SIB–IMRT (n=9) or IMRT (2 Gy/fraction, 35 fractions, n=9)]. The control group consisted of healthy individuals. IL-6 and TGF-β concentrations were determined by ELISA and CRP by an immunoturbidimetric method before treatment, 2 and 4 weeks after treatment started, at the end of treatment, and 4 weeks post-treatment. Results: IL-6 levels were higher in the treatment group compared to controls and increased at all-time points compared to pre-treatment levels (P Conclusions: Serum levels of proinflammatory markers, IL-6 and CRP are increased after radiotherapy and radiochemotherapy in patients with head and neck cancers. The adverse effects of IL-6 and CRP could by suppressed by concomitantly decreased TGF-β levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
